BNF 83 (British National Formulary) March 2022

Product Information

Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia [MHRA/CHM advice] (advice in calcium gluconate). The BNF is jointly published by the Royal Pharmaceutical Society and BMJ. BNF is published in print twice a year and interim updates are issued and published monthly in the digital versions. The following summary provides a brief description of some recent key changes that have been made to BNF content. Tranexamic acid [update to dosing for prevention and treatment of significant haemorrhage following major trauma].

Lamotrigine | Drugs | BNF | NICE

This edition of BNF continues to broadly follow the high-level structure of previous editions of BNF. Preliminary material, including information on how to use the BNF, significant changes to the content in each edition, and guidance on various prescribing issues (eg, prescription writing, use of intravenous medications, particular considerations for special patient populations). Chapters, which contain drug monographs that describe the uses, dosages, safety issues, and other considerations involved in drug use; drug class monographs; and treatment summaries, which include guidance on medication selection. Treatment monographs and summaries are divided into chapters based on specific aspects of medical care, such as Chapter 5, Infections, or Chapter 16, Emergency Treatment of Poisoning; or drug use related to a particular body system, such as Chapter 2, Cardiovascular. Vaccines update [classifications changed to Vaccines, live or Vaccines, inactivated and non-replicating].Vaccines update: restructure of Influenza vaccine monograph—creation of monographs for influenza vaccine (live) and influenza vaccine (inactivated). This update contains 3 significant changes, 1 dose change, 3 new monographs, and 3 deleted monographs. Oral iron: updated dosing and monitoring advice for iron-deficiency anaemia based on British Society of Gastroenterology guidelines (advice in ferrous sulfate, ferrous sulfate with ascorbic acid, ferrous fumarate, ferrous gluconate, ferric maltol, sodium feredetate; see example in ferrous sulfate). Clarithromycin [update to include dosing for prevention of invasive group A streptococcal infection in children from 6 months old and adults]. Controlled drugs and drug dependence: updated guidance on prescription requirements for Schedule 2 and 3 Controlled Drugs.

BNF 83 (British National Formulary) March 2022 - Waterstones

Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure [MHRA/CHM advice] (see advice in Aromatic inhalations, cough preparations and systemic nasal decongestants). Aminoglycosides: pre-treatment screening advice on genetic testing for aminoglycoside exposure posing risk to hearing (advice in relevant monographs; see example in gentamicin). This update contains 6 significant changes, 1 dose change, 2 new monographs, 1 new preparation, 4 deleted monographs, and 1 deleted preparation. Hyoscine hydrobromide patches ( Scopoderm® 1.5 mg patch or Scopoderm® TTS patch): risk of anticholinergic side effects, including hyperthermia [MHRA/CHM advice]. Drugs that cause hepatotoxicity, drugs with CNS depressant effects, and drugs that increase serum potassium: pharmacodynamic effects drug groups revalidated and updated; see Appendix 1 interactions.Specialist drug” monographs within BNF Publications: identification and reduced level of detail, see How to use BNF Publications online.